Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development

References

• Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020 02;75(2):423–432. doi: 10.1111/all.14037
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022 Mar;77(3):734–766. doi: 10.1111/all.15090
   PubMed Web of Science ®Google Scholar
• Maurer M, Zuberbier T, Metz M. The classification, pathogenesis, diagnostic workup, and management of urticaria: an update. Handb Exp Pharmacol. 2022;268:117–133. doi: 10.1007/164_2021_506
   PubMedGoogle Scholar
• Kaplan A, Lebwohl M, Giménez-Arnau AM, et al. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. Allergy. 2023 Feb;78(2):389–401. doi: 10.1111/all.15603
   PubMed Web of Science ®Google Scholar
• Kocatürk E, Grattan C. Is chronic urticaria more than skin deep? Clin Transl Allergy. 2019 Sep 25;9(48): 2. eCollection 2019. doi: 10.1186/s13601-019-0287-2
   PubMedGoogle Scholar
• Kolkhir P, Elieh-Ali-Komi D, Metz M, et al. Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nat Rev Immunol. 2022 May;22(5):294–308. doi: 10.1038/s41577-021-00622-y
   PubMed Web of Science ®Google Scholar
• Smith CH, Kepley C, Schwartz LB, et al. Mast cell number and phenotype in chronic idiopathic urticaria. J Allergy Clin Immunol. 1995 Sep;96(3):360–364. doi: 10.1016/S0091-6749(95)70055-2
   PubMed Web of Science ®Google Scholar
• Giménez-Arnau AM, DeMontojoye L, Asero R, et al. The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells. J Allergy Clin Immunol Pract. 2021 Jun;9(6):2195–2208. doi: 10.1016/j.jaip.2021.03.033
   PubMed Web of Science ®Google Scholar
• Ying S, Kikuchi Y, Meng Q, et al. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol. 2002;109(4):694–700. doi: 10.1067/mai.2002.123236
   PubMed Web of Science ®Google Scholar
• Maurer M, Khan DA, Elieh Ali Komi D, et al. Biologics for the use in chronic spontaneous urticaria: when and which. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1067–1078. doi: 10.1016/j.jaip.2020.11.043
   PubMed Web of Science ®Google Scholar
• Oliver ET, Sterba PM, Saini SS. Interval shifts in basophil measures correlate with disease activity in chronic spontaneous urticaria. Allergy. 2015 May;70(5):601–603. doi: 10.1111/all.12578
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Church MK, Altrichter S, et al. Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment. J Allergy Clin Immunol Pract. 2020 Jan;8(1):318,325.e5. doi: 10.1016/j.jaip.2019.08.025
   Web of Science ®Google Scholar
• Grattan CE, Dawn G, Gibbs S, et al. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy. 2003 Mar;33(3):337–341. doi: 10.1046/j.1365-2222.2003.01589.x
   PubMed Web of Science ®Google Scholar
• Asero R, Cugno M. Biomarkers of chronic spontaneous urticaria and their clinical implications. Expert Rev Clin Immunol. 2021 Mar 1;17(3):247–254. doi: 10.1080/1744666X.2021.1882304
   PubMed Web of Science ®Google Scholar
• Michel M, Klingebiel C, Vitte J. Tryptase in type I hypersensitivity. Ann Allergy Asthma Immunol. 2023 Feb;130(2):169–177. doi: 10.1016/j.anai.2022.08.996
   PubMed Web of Science ®Google Scholar
• Schwartz LB, Bradford TR, Rouse C, et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol. 1994 May;14(3):190–204. doi: 10.1007/BF01533368
   PubMed Web of Science ®Google Scholar
• Ferrer M, Nuñez-Córdoba JM, Luquin E, et al. Serum total tryptase levels are increased in patients with active chronic urticaria. Clin Exp Allergy. 2010 Dec;40(12):1760–1766. doi: 10.1111/j.1365-2222.2010.03582.x
   PubMed Web of Science ®Google Scholar
• Deleuran B, Kristensen M, Larsen CG, et al. Increased tryptase levels in suction-blister fluid from patients with urticaria. Br J Dermatol. 1991 Jul;125(1):14–17. doi: 10.1111/j.1365-2133.1991.tb06031.x
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Giménez-Arnau AM, Kulthanan K, et al. Urticaria. Nat Rev Dis Primers. 2022 Sep 15;8(1):61–z. doi: 10.1038/s41572-022-00389-z
   PubMedGoogle Scholar
• Zhang Y, Zhang H, Du S, et al. Advanced biomarkers: therapeutic and diagnostic targets in urticaria. Int Arch Allergy Immunol. 2021;182(10):917–931. doi: 10.1159/000515753
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Gimenez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017 Apr;72(4):519–533. doi: 10.1111/all.13083
   PubMed Web of Science ®Google Scholar
• Wedi B, Traidl S. Anti-IgE for the treatment of chronic urticaria. Immunotargets Ther. 2021 Feb 17;10:27–45. doi: 10.2147/ITT.S261416
   PubMed Web of Science ®Google Scholar
• Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “real-world” evidence. JAMA Dermatol. 2019 Jan 1;155(1):29–38. doi: 10.1001/jamadermatol.2018.3447
   PubMed Web of Science ®Google Scholar
• Metz M, Vadasz Z, Kocaturk E, et al. Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence. Clin Rev Allergy Immunol. 2020 Aug 1;59(1):38–45. doi: 10.1007/s12016-020-08794-6
   PubMed Web of Science ®Google Scholar
• Wedi B. Emerging treatments for chronic urticaria. Expert Opin Investig Drugs. 2022 Mar;31(3):281–290. doi: 10.1080/13543784.2022.2042513
   PubMed Web of Science ®Google Scholar
• Yuzawa S, Opatowsky Y, Zhang Z, et al. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell. 2007 Jul 27;130(2):323–334. doi: 10.1016/j.cell.2007.05.055
   PubMed Web of Science ®Google Scholar
• Kimura Y, Ding B, Imai N, et al. C-kit-mediated functional positioning of stem cells to their niches is essential for maintenance and regeneration of adult hematopoiesis. PLoS One. 2011;6(10):e26918. doi: 10.1371/journal.pone.0026918
   PubMed Web of Science ®Google Scholar
• Tallini YN, Greene KS, Craven M, et al. C-kit expression identifies cardiovascular precursors in the neonatal heart. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1808–1813. doi: 10.1073/pnas.0808920106
   PubMed Web of Science ®Google Scholar
• Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol. 1999 Oct;31(10):1037–1051. doi: 10.1016/S1357-2725(99)00076-X
   PubMed Web of Science ®Google Scholar
• Broudy VC. Stem cell factor and hematopoiesis. Blood. 1997 Aug 15;90(4):1345–1364. doi: 10.1182/blood.V90.4.1345
   PubMed Web of Science ®Google Scholar
• Tsai M, Takeishi T, Thompson H, et al. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6382–6386. doi: 10.1073/pnas.88.14.6382
   PubMed Web of Science ®Google Scholar
• Ito T, Smrž D, Jung M, et al. Stem cell factor programs the mast cell activation phenotype. J Immunol. 2012 Jun 1;188(11):5428–5437. doi: 10.4049/jimmunol.1103366
   PubMed Web of Science ®Google Scholar
• Al-Azzam N, Kondeti V, Duah E, et al. Modulation of mast cell proliferative and inflammatory responses by leukotriene d4 and stem cell factor signaling interactions. J Cell Physiol. 2015 Mar;230(3):595–602. doi: 10.1002/jcp.24777
   PubMed Web of Science ®Google Scholar
• Fleischman RA, Gallardo T, Mi X. Mutations in the ligand-binding domain of the kit receptor: an uncommon site in human piebaldism. J Invest Dermatol. 1996 Nov;107(5):703–706. doi: 10.1111/1523-1747.ep12365596
   PubMed Web of Science ®Google Scholar
• Pittoni P, Piconese S, Tripodo C, et al. Tumor-intrinsic and -extrinsic roles of c-kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene. 2011 Feb 17;30(7):757–769. doi: 10.1038/onc.2010.494
   PubMed Web of Science ®Google Scholar
• Sartini S, Dario B, Morelli M, et al. Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview. Curr Med Chem. 2011;18(19):2893–2903. doi: 10.2174/092986711796150504
   PubMed Web of Science ®Google Scholar
• Orfao A, Garcia-Montero AC, Sanchez L, et al. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol. 2007 Jul;138(1):12–30. doi: 10.1111/j.1365-2141.2007.06619.x.
   PubMed Web of Science ®Google Scholar
• Verstovsek S. Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol. 2013 Feb 1;90(2):89–98. doi: 10.1111/ejh.12043
   PubMed Web of Science ®Google Scholar
• Tsai M, Valent P, Galli SJ. KIT as a master regulator of the mast cell lineage. J Allergy Clin Immunol. 2022 Jun;149(6):1845–1854. doi: 10.1016/j.jaci.2022.04.012
   PubMed Web of Science ®Google Scholar
• Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-kit as targets for inflammatory diseases. Eur J Pharmacol. 2006 Mar 8;533(1–3):327–340. doi: 10.1016/j.ejphar.2005.12.067
   PubMed Web of Science ®Google Scholar
• Heinemann A, Sturm GJ, Ofner M, et al. Stem cell factor stimulates the chemotaxis, integrin upregulation, and survival of human basophils. J Allergy Clin Immunol. 2005 Oct;116(4):820–826. doi: 10.1016/j.jaci.2005.06.008
   PubMed Web of Science ®Google Scholar
• Yuan Q, Austen KF, Friend DS, et al. Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1). J Exp Med. 1997 Jul 21;186(2):313–323. doi: 10.1084/jem.186.2.313
   PubMed Web of Science ®Google Scholar
• Oliveira SHP, Taub DD, Nagel J, et al. Stem cell factor induces eosinophil activation and degranulation: mediator release and gene array analysis. Blood. 2002 Dec 15;100(13):4291–4297. doi: 10.1182/blood.V100.13.4291
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science. 2002 Dec 6;298(5600):1912–1934. doi: 10.1126/science.1075762
   PubMed Web of Science ®Google Scholar
• Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000 Nov 20;19(49):5548–5557. doi: 10.1038/sj.onc.1203957
   PubMed Web of Science ®Google Scholar
• Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol. 2020 Oct 27;13(1):143–0. doi: 10.1186/s13045-020-00977-0
   PubMed Web of Science ®Google Scholar
• Gotlib J, Reiter A, Radia DH, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021 Dec;27(12):2192–2199. doi: 10.1038/s41591-021-01539-8
   PubMed Web of Science ®Google Scholar
• Sriskandarajah P, McLornan DP, Oni C, et al. Advanced systemic mastocytosis with associated haematological neoplasm: treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant. Curr Res Transl Med. 2023 Jun 13;71(3):103398. doi: 10.1016/j.retram.2023.103398
   PubMed Web of Science ®Google Scholar
• Degenfeld-Schonburg L, Gamperl S, Stefanzl G, et al. Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V(+) systemic mastocytosis: a preclinical study. Am J Cancer Res. 2023 Feb 15;13(2):355–378.
   PubMed Web of Science ®Google Scholar
• Kannaiyan R, Mahadevan D. A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther. 2018 Dec;18(12):1249–1270. doi: 10.1080/14737140.2018.1527688
   PubMed Web of Science ®Google Scholar
• Valent P, Akin C, Hartmann K, et al. Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders? J Allergy Clin Immunol. 2022 Jun;149(6):1866–1874. doi: 10.1016/j.jaci.2022.04.003
   PubMed Web of Science ®Google Scholar
• Lee DM, Friend DS, Gurish MF, et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002 Sep 6;297(5587):1689–1692. doi: 10.1126/science.1073176
   PubMed Web of Science ®Google Scholar
• Tebib J, Mariette X, Bourgeois P, et al. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther. 2009;11(3):R95. doi: 10.1186/ar2740
   PubMed Web of Science ®Google Scholar
• Kraft M, Martin RJ, Lazarus SC, et al. Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids. Chest. 2003 Jul;124(1):42–50. doi: 10.1378/chest.124.1.42
   PubMed Web of Science ®Google Scholar
• Cahill KN, Katz HR, Cui J, et al. KIT inhibition by imatinib in patients with severe refractory asthma. N Engl J Med. 2017 May 18;376(20):1911–1920. doi: 10.1056/NEJMoa1613125
   PubMed Web of Science ®Google Scholar
• Humbert M, de Blay F, Garcia G, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy. 2009 Aug;64(8):1194–1201. doi: 10.1111/j.1398-9995.2009.02122.x
   PubMed Web of Science ®Google Scholar
• Davidescu L, Ursol G, Korzh O, et al. Efficacy and safety of masitinib in corticosteroid-dependent severe asthma: a randomized placebo-controlled trial. J Asthma Allergy. 2022 Jun 7;15:737–747. doi: 10.2147/JAA.S337284
   PubMed Web of Science ®Google Scholar
• London CA, Gardner HL, Rippy S, et al. KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells. Clin Cancer Res. 2017 May 15;23(10):2565–2574. doi: 10.1158/1078-0432.CCR-16-2152
   PubMed Web of Science ®Google Scholar
• Reshetnyak AV, Nelson B, Shi X, et al. Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region. Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17832–17837. doi: 10.1073/pnas.1317118110
   PubMed Web of Science ®Google Scholar
• Garton AJ, Seibel S, Lopresti-Morrow L, et al. Anti-KIT monoclonal antibody treatment enhances the antitumor activity of immune checkpoint inhibitors by reversing tumor-induced immunosuppression. Mol Cancer Ther. 2017 Apr;16(4):671–680. doi: 10.1158/1535-7163.MCT-16-0676
   PubMed Web of Science ®Google Scholar
• Stahl M, Gedrich R, Peck R, et al. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors. Immunotherapy. 2016 Jun;8(7):767–774. doi: 10.2217/imt-2016-0040
   PubMed Web of Science ®Google Scholar
• Ashman LK, Bühring HJ, Aylett GW, et al. Epitope mapping and functional studies with three monoclonal antibodies to the c-kit receptor tyrosine kinase, YB5.B8, 17F11, and SR-1. J Cell Physiol. 1994 Mar;158(3):545–554. doi: 10.1002/jcp.1041580321
   PubMed Web of Science ®Google Scholar
• Seibel S, Vitale L, Thomas L, et al. D100 cdx-0159, an anti-kit monoclonal antibody, as a modulator of mast cell-related diseases. Ann Allergy Asthma Immunol. 2019;123(5, Supplement):S14. doi: 10.1016/j.anai.2019.08.069
   Web of Science ®Google Scholar
• Mandel EM. Regulation of airway eosinophilia in a model offline allergic asthma by ktn0158, a humanized anti-kit monoclonal antibody. Ann Allergy Asthma Immunol. 2014;113(5):A48.
   PubMed Web of Science ®Google Scholar
• Alvarado D, Maurer M, Gedrich R, et al. Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy. 2022 Aug;77(8):2393–2403. doi: 10.1111/all.15262
   PubMed Web of Science ®Google Scholar
• Borrok MJ, Mody N, Lu X, et al. An “fc-silenced” IgG1 format with extended half-life designed for improved stability. J Pharm Sci. 2017 Apr;106(4):1008–1017. doi: 10.1016/j.xphs.2016.12.023
   PubMed Web of Science ®Google Scholar
• Hezareh M, Hessell AJ, Jensen RC, et al. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol. 2001 Dec;75(24):12161–12168. doi: 10.1128/JVI.75.24.12161-12168.2001
   PubMed Web of Science ®Google Scholar
• Dall’acqua WF, Cook KE, Damschroder MM, et al. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol. 2006 Jul 15;177(2):1129–1138. doi: 10.4049/jimmunol.177.2.1129
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall’acqua WF, et al. A novel investigational fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013 Dec;57(12):6147–6153. doi: 10.1128/AAC.01285-13
   PubMed Web of Science ®Google Scholar
• Celldex therapeutics annual report 2023. 2023 Feb 28th. [cited Sep 26, 2023]. Available from: https://stocklight.com/stocks/us/manufacturing/nasdaq-cldx/celldex-therapeutics/annual-reports/nasdaq-cldx-2023-10K-23685135.pdf
   Google Scholar
• Terhorst-Molawi D, Hawro T, Grekowitz E, et al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2023 May 1;78(5):1269–1279. doi: 10.1111/all.15585
   PubMed Web of Science ®Google Scholar
• McLaughlin SK. Erb and c-kit receptors have distinctive patterns of expression in adult and developing taste papillae and taste buds. J Neurosci. 2000 Aug 1;20(15):5679–5688. doi: 10.1523/JNEUROSCI.20-15-05679.2000
   PubMed Web of Science ®Google Scholar
• Jasper therapeutics. Manufacturer website with information about briquilimab. [2023 Sep 26]. Available from: http://www.jaspertherapeutics.com/briquilimab
   Google Scholar
• Kwon H, Logan AC, Chhabra A, et al. Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. Blood. 2019 May 9;133(19):2104–2108. doi: 10.1182/blood-2018-06-853879
   PubMed Web of Science ®Google Scholar
• Griffin JM, Healy FM, Dahal LN, et al. Worked to the bone: antibody-based conditioning as the future of transplant biology. J Hematol Oncol. 2022 May 19;15(1):65–66. doi: 10.1186/s13045-022-01284-6
   PubMed Web of Science ®Google Scholar
• Pang WW, Czechowicz A, Logan AC, et al. Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. Blood. 2019 May 9;133(19):2069–2078. doi: 10.1182/blood-2018-06-858159
   PubMed Web of Science ®Google Scholar
• Muffly LS, Chin M, Kwon H-S, et al. Early results of phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with non-myeloablative conditioning in older adults with MRD-positive MDS/AML undergoing allogenic hematopoietic cell transplantation. ASCO Annu. Meet; 2021. [cited Oct 23, 2023]. Available from: https://meetings.asco.org/abstracts-presentations/195820
   Google Scholar
• Muffly LS, Kwon H-S, Chin M, et al. Phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with low dose irradiation and fludarabine in older adults with MRD-positive AML/MDS undergoing allogeneic HCT. Transplant. Cell. Ther. Meet; 2021. [cited Oct 23, 2023]. Available from: http://www.jaspertherapeutics.com/wp-content/uploads/2021/08/TCT2021_MDS-AML-SUBMITTED-Poster.pdf
   Google Scholar
• Agarwal R, Dvorak CC, Kwon H-S, et al. Non-genotoxic anti-CD117 antibody conditioning results in successful hematopoietic stem cell engraftment in patients with severe combined immunodeficiency. Blood. 2019;134(Supplement 1):800. doi: 10.1182/blood-2019-126239
   Google Scholar
• Jasper therapeutics inc. To present data on JSP191 conditioning in SCID patients at the 2021 American society of hematology annual meeting. [cited 2023 Oct 23]. Available from: https://ir.jaspertherapeutics.com/node/7416/pdf
   Google Scholar
• Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021 Jun;18(6):327–344. doi: 10.1038/s41571-021-00470-8
   PubMed Web of Science ®Google Scholar
• Celldex Manufacturer website with information about barzolvolimab and anti-KIT pipeline. [2023 Sep 26]. Available from: https://celldex.com/pipeline/overview/
   Google Scholar
• Acelyrin. Manufacturer website with information about SLRN-517. [cited 2023 Sep 26]. Available from: https://acelyrin.com/SLRN-517
   Google Scholar
• Mendes-Bastos P, Brasileiro A, Kolkhir P, et al. Bruton’s tyrosine kinase inhibition-an emerging therapeutic strategy in immune-mediated dermatological conditions. Allergy. 2022 Aug 1;77(8):2355–2366. doi: 10.1111/all.15261
   PubMed Web of Science ®Google Scholar
• Maurer M, Berger W, Gimenez-Arnau A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol. 1506 2 2022 Dec 1;150(6):1498. doi: 10.1016/j.jaci.2022.08.027
   Google Scholar
• Celldex. Manufacturer website. Press Release Regarding CDX-622. [Sep 26, 2023]. Available from: https://ir.celldex.com/node/14961/pdf
   Google Scholar